Core Insights - Coloplast reported organic growth of 7% and an EBIT margin of 28% in Q3 2024/25, with reported revenue in DKK growing by 1% [1][4] - For the first nine months of 2024/25, organic growth remained at 7% with reported revenue increasing by 4% to DKK 20,914 million [2][4] - The company maintains its FY 2024/25 guidance for organic growth around 7% and an EBIT margin before special items of 27-28% [3][4] Financial Performance - EBIT for Q3 was DKK 1,915 million, a 2% increase from the previous year, with an EBIT margin of 28% compared to 27% last year [4] - Adjusted net profit before special items was DKK 3,778 million, a decrease of DKK 15 million from last year, with adjusted diluted EPS before special items decreasing by 1% to DKK 16.76 [4] - The reported growth in DKK is now expected to be 3-4%, with negative impacts from currency fluctuations and the Skin Care divestment [4] Business Segment Performance - Organic growth rates by business area include: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4%, and Interventional Urology 4% [4] - Advanced Wound Care experienced a decline of -2% primarily due to a product return in China, expected to negatively impact revenue by around DKK 80 million in H2 [4] - Kerecis grew by 17% with a 13% EBIT margin before PPA amortization, although growth was impacted by a slowdown in the outpatient setting [4] Strategic Developments - Changes to the Executive Leadership Team were announced to support the execution of the new company strategy towards 2030 [4][5] - The search for Coloplast's new CEO is ongoing, with a presentation of the 2030 strategy planned for the Capital Markets Day on 2 September [5]

Roadshow presentation 9M 2024/25 Making life easier Strive25: Sustainable Growth Leadership Fikria , User, Continence Care Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the ...